Report Overview

China Lysosomal Storage Disorders Therapeutics market size stood at around USD xx billion in 2019 and is projected to reach USD $xx billion by 2028, exhibiting a CAGR of 5.2% during the forecast period.

Lysosomal storage diseases are inherited metabolic diseases that are characterized by an abnormal build-up of various toxic materials in the bodys cells as a result of enzyme deficiencies. Although each type of lysosomal storage disease is very rare, as a whole, the global incidence is about 1 in 5000-6000. Taking Shanghai as an example, about 200,000 newborns are born in the city each year, and the number of patients About 10-20.



Market Drivers

China is a growing market for lysosomal storage disorders due to an enormous population, increase in awareness of disease by the establishment of the Chinese Newborns Screening Cooperative Group for Lysosomal Storage Disease and improvement in R&D activities. Development of novel therapeutics and increase in global incidence (1 in 5000-6000) and prevalence rate leads to growth of the China lysosomal Storage Disorders drug market.

However, there are some restraining factors for the growth of lysosomal storage disorders therapeutics market in China such as high cost of treatment, limitations of medical insurance coverage and misdiagnosis of the disease (in 2019 61.9% of Gaucher disease patients have experienced misdiagnosis, and 27.9% of patients need 1-5 years to be diagnosed).